We are live on ! Find out more
RM

RP Management Portfolio holdings

AUM $139M
1-Year Est. Return 37.98%
This Fund
S&P 500
This Quarter Est. Return
+83.1%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$442M
AUM Growth
+$286M
Cap. Flow
+$99M
Cap. Flow %
22.37%
Top 10 Hldgs %
100%
Holding
6
New
2
Increased
–
Reduced
–
Closed
–
Avg Time Held Equity + Options
2.7 quarters
Top 10 Avg Time Held Equity + Options
2.7 quarters
Top 20 Avg Time Held Equity + Options
2.7 quarters
Avg Time Held Equity only
3.2 quarters
Top 10 Avg Time Held Equity only
3.2 quarters
Top 20 Avg Time Held Equity only
3.2 quarters

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$99M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 86.1%
2 Miscellaneous 13.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EPZM
1
DELISTED
Epizyme, Inc
EPZM
$164M 37.08%
+6,666,667
New +$99M
2019 Q4
0 quarters
BHVN icon
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$115M 25.98%
2,111,111
– –
2018 Q4
4 quarters
IMMU
3
DELISTED
Immunomedics Inc
IMMU
$92.5M 20.92%
4,373,178
– –
2018 Q4
4 quarters
EPZM
4
CALL
DELISTED
Epizyme, Inc
EPZM
$61.5M 13.9%
+2,500,000
New +$37.1M
2019 Q4
0 quarters
CYTK icon
5
Cytokinetics
CYTK
$8.73B
$9.29M 2.1%
875,656
– –
2018 Q4
4 quarters
VIRX icon
6
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$44K 0.01%
3,700
– –
2018 Q4
4 quarters

Similar funds

PC
Paradoxiom Capital Stamford, Connecticut $154M AUM
LA
LPF Advisors Sarasota, Florida $122M AUM 3.12% 1-Year Est. Return
TP
Thunderbird Partners London, United Kingdom $113M AUM 8.51% 1-Year Est. Return
SC
Serenity Capital Palo Alto, California $167M AUM
MADFP
Michael A Dubis Financial Planning Middleton, Wisconsin $103M AUM
RM
RCF Management Denver, Colorado $103M AUM
NC
Napatree Capital Westerly, Rhode Island $178M AUM 8.09% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

RP Management's Q4 2019 Portfolio in Review

As of Q4 2019, RP Management held 6 positions worth $442M, up 183% from $156M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

RP Management deployed $99M of net new capital in Q4 2019, opening 2 new positions. Its largest new stake was Epizyme, Inc: 6,666,667 shares worth $164M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • RP Management's largest Q4 2019 buy was Epizyme, Inc: 6,666,667 shares worth $164M.
  • RP Management's ten largest holdings make up 100% of its $442M portfolio in Q4 2019.
  • RP Management opened 2 new positions and closed 0 in Q4 2019.
  • RP Management's portfolio value rose 183% quarter-over-quarter to $442M.

Based on RP Management's 13F filing for Q4 2019, filed 14 Feb 2020.